Efficacy evaluation of traditional Chinese medicine combined with sorafenib in the treatment of primary hepatocellular carcinoma in the middle and late stage

中国临床实用医学 Pub Date : 2016-04-25 DOI:10.3760/CMA.J.ISSN.1673-8799.2016.02.002

Yue Wu, Benqiang Yang, Wen-yuan Liu

{"title":"Efficacy evaluation of traditional Chinese medicine combined with sorafenib in the treatment of primary hepatocellular carcinoma in the middle and late stage","authors":"Yue Wu, Benqiang Yang, Wen-yuan Liu","doi":"10.3760/CMA.J.ISSN.1673-8799.2016.02.002","DOIUrl":null,"url":null,"abstract":"Objective \nEvaluation of the treatment effects between sorafenib soley and by combination of SLFN and Chinese Medicine on mid to later phase hepatic carcinomas patients. \n \n \nMethods \nTake 48 mid to later phase hepatic carcinomas patients of our hospital from 2010 to 2015. Randomly assign 24 patients to sorafenib group and 24 to sorafenib combine Chinese medicine group. To compare the change of their liver function and multilayer spiral MSCT image. \n \n \nResults \nThere were no significant statistical difference between the two groups on size of the tumors, liver diffusion outside, cancer embolus of portal vein(P>0.05). But there were meaningful statistical difference on TBIL, DBIL, ALT, ALB and GLB(P<0.05). \n \n \nConclusions \nCompare to chemotherapy only method, there are no different results on tumor growth and diffusion by combing with Chinese Medicine with sorafenib, but there are some effect on improving liver function and life quality. \n \n \nKey words: \nPrimary hepatocellular carcinoma; Chinese medicine treatment; Multi-layer spiral CT","PeriodicalId":64135,"journal":{"name":"中国临床实用医学","volume":"7 1","pages":"3-5"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国临床实用医学","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-8799.2016.02.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective Evaluation of the treatment effects between sorafenib soley and by combination of SLFN and Chinese Medicine on mid to later phase hepatic carcinomas patients. Methods Take 48 mid to later phase hepatic carcinomas patients of our hospital from 2010 to 2015. Randomly assign 24 patients to sorafenib group and 24 to sorafenib combine Chinese medicine group. To compare the change of their liver function and multilayer spiral MSCT image. Results There were no significant statistical difference between the two groups on size of the tumors, liver diffusion outside, cancer embolus of portal vein(P>0.05). But there were meaningful statistical difference on TBIL, DBIL, ALT, ALB and GLB(P<0.05). Conclusions Compare to chemotherapy only method, there are no different results on tumor growth and diffusion by combing with Chinese Medicine with sorafenib, but there are some effect on improving liver function and life quality. Key words: Primary hepatocellular carcinoma; Chinese medicine treatment; Multi-layer spiral CT

查看原文本刊更多论文

中药联合索拉非尼治疗原发性中晚期肝癌的疗效评价

目的评价索拉非尼单抗与单宁联合中药治疗中晚期肝癌的疗效。方法选取我院2010 ~ 2015年收治的中晚期肝癌患者48例。随机选择索拉非尼组24例，索拉非尼联合中药组24例。比较其肝功能变化与多层螺旋MSCT图像的差异。结果两组患者肿瘤大小、肝外扩散、门静脉癌栓等指标比较，差异均无统计学意义(P < 0.05)。TBIL、DBIL、ALT、ALB、GLB差异有统计学意义(P<0.05)。结论与单纯化疗相比，中药联合索拉非尼对肿瘤生长和扩散无明显差异，但在改善肝功能和生活质量方面有一定作用。关键词:原发性肝癌;中医治疗;多层螺旋CT

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国临床实用医学

自引率

0.00%

发文量

6167